Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function
Cinacalcet use is associated with risk of hypocalcemia; however, this risk has been mostly demonstrated in patients with chronic kidney disease. In this article, we describe a case of a 59-year-old male with primary hyperparathyroidism (PHPT), hypercalciuria, osteopenia, and normal kidney function w...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-06-01
|
| Series: | Journal of Investigative Medicine High Impact Case Reports |
| Online Access: | https://doi.org/10.1177/2324709620936836 |
| _version_ | 1819227619148693504 |
|---|---|
| author | Son Nguyen DO, PharmD Elvira O. Gosmanova MD Aidar R. Gosmanov MD, PhD, FACE |
| author_facet | Son Nguyen DO, PharmD Elvira O. Gosmanova MD Aidar R. Gosmanov MD, PhD, FACE |
| author_sort | Son Nguyen DO, PharmD |
| collection | DOAJ |
| description | Cinacalcet use is associated with risk of hypocalcemia; however, this risk has been mostly demonstrated in patients with chronic kidney disease. In this article, we describe a case of a 59-year-old male with primary hyperparathyroidism (PHPT), hypercalciuria, osteopenia, and normal kidney function who was started on cinacalcet for the management of recurrent hypercalcemia following prior unsuccessful parathyroidectomy. Within 6 months following cinacalcet commencement, he developed symptomatic and biochemical hypocalcemia requiring discontinuation of the medication and initiation of calcium supplementation. Over more than 3 years of follow-up, his calcium supplementation was gradually tapered off and then discontinued. He is presently eucalcemic and euparathyroid off calcium supplements while also demonstrating normalization of hypercalciuria and bone mineral density. These data indicate that our patient has experienced resolution of PHPT after brief exposure to cinacalcet. We recommend that low starting cinacalcet doses should be considered for treatment of hypercalcemia in patients with PHPT who underwent unsuccessful parathyroidectomy along with close clinical and biochemical follow-up. |
| first_indexed | 2024-12-23T10:44:16Z |
| format | Article |
| id | doaj.art-6543819eca4c443281c2ea5f428e32d8 |
| institution | Directory Open Access Journal |
| issn | 2324-7096 |
| language | English |
| last_indexed | 2024-12-23T10:44:16Z |
| publishDate | 2020-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Investigative Medicine High Impact Case Reports |
| spelling | doaj.art-6543819eca4c443281c2ea5f428e32d82022-12-21T17:50:05ZengSAGE PublishingJournal of Investigative Medicine High Impact Case Reports2324-70962020-06-01810.1177/2324709620936836Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney FunctionSon Nguyen DO, PharmD0Elvira O. Gosmanova MD1Aidar R. Gosmanov MD, PhD, FACE2Department of Medicine, Albany Medical College, Albany, NY, USANephrology Section, Stratton VA Medical Center, Albany, NY, USAEndocrinology Section, Stratton VA Medical Center, Albany, NY, USACinacalcet use is associated with risk of hypocalcemia; however, this risk has been mostly demonstrated in patients with chronic kidney disease. In this article, we describe a case of a 59-year-old male with primary hyperparathyroidism (PHPT), hypercalciuria, osteopenia, and normal kidney function who was started on cinacalcet for the management of recurrent hypercalcemia following prior unsuccessful parathyroidectomy. Within 6 months following cinacalcet commencement, he developed symptomatic and biochemical hypocalcemia requiring discontinuation of the medication and initiation of calcium supplementation. Over more than 3 years of follow-up, his calcium supplementation was gradually tapered off and then discontinued. He is presently eucalcemic and euparathyroid off calcium supplements while also demonstrating normalization of hypercalciuria and bone mineral density. These data indicate that our patient has experienced resolution of PHPT after brief exposure to cinacalcet. We recommend that low starting cinacalcet doses should be considered for treatment of hypercalcemia in patients with PHPT who underwent unsuccessful parathyroidectomy along with close clinical and biochemical follow-up.https://doi.org/10.1177/2324709620936836 |
| spellingShingle | Son Nguyen DO, PharmD Elvira O. Gosmanova MD Aidar R. Gosmanov MD, PhD, FACE Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function Journal of Investigative Medicine High Impact Case Reports |
| title | Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function |
| title_full | Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function |
| title_fullStr | Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function |
| title_full_unstemmed | Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function |
| title_short | Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function |
| title_sort | cinacalcet associated resolution of primary hyperparathyroidism in a patient with normal kidney function |
| url | https://doi.org/10.1177/2324709620936836 |
| work_keys_str_mv | AT sonnguyendopharmd cinacalcetassociatedresolutionofprimaryhyperparathyroidisminapatientwithnormalkidneyfunction AT elviraogosmanovamd cinacalcetassociatedresolutionofprimaryhyperparathyroidisminapatientwithnormalkidneyfunction AT aidarrgosmanovmdphdface cinacalcetassociatedresolutionofprimaryhyperparathyroidisminapatientwithnormalkidneyfunction |